Evidence map›Paper›PMID 32131814›Full record

ArticleBMC health services research2020

Challenges with scale-up of GeneXpert MTB/RIF® in Uganda: a health systems perspective.

Talemwa Nalugwa, Priya B Shete, Mariam Nantale, Katherine Farr, Christopher Ojok, Emma Ochom, Frank Mugabe, Moses Joloba, David W Dowdy, David A J Moore and 3 more

Abstract read
In one paragraph

Article in BMC health services research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Patient preferences for empiric TB treatment initiation.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Talemwa NalugwaDepartment of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
Priya B SheteUganda Tuberculosis Implementation Research Consortium, Kampala, Uganda. priya.shete@ucsf.edu.ORCID http://orcid.org/0000-0002-0279-8170
Mariam NantaleDepartment of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
Katherine FarrUganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.
Christopher OjokDepartment of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
Emma OchomDepartment of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
Frank MugabeUganda National Tuberculosis and Leprosy Control Programme, Kampala, Uganda.
Moses JolobaUganda National Tuberculosis and Leprosy Control Programme, Kampala, Uganda.
David W DowdyDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
David A J MooreFaculty of Infectious and Tropical Diseases and TB Centre, London School of Hygiene and Tropical Medicine, London, UK.
J Lucian DavisDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Adithya CattamanchiUganda Tuberculosis Implementation Research Consortium, Kampala, Uganda.
Achilles KatambaDepartment of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
SIngle-saMPLE tuberculosis evaluation to facilitate linkage to care: The SIMPLE TB trialR01HL130192 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CATTAMANCHI, ADITHYA · 2016 to 2020
$3.2M
Medical Research Council MR/M017362/1NCATS NIH HHS UL1 TR001863NHLBI NIH HHS R01 HL130192NIH HHS HL130192Wellcome TrustWellcome Trust MR/M017362/1
6 · The paper itself

Abstract

backgroundMany high burden countries are scaling-up GeneXpert® MTB/RIF (Xpert) testing for tuberculosis (TB) using a hub-and-spoke model. However, the effect of scale up on reducing TB has been limited. We sought to characterize variation in implementation of referral-based Xpert TB testing across Uganda, and to identify health system factors that may enhance or prevent high-quality implementation of Xpert testing services.

methodsWe conducted a cross-sectional study triangulating quantitative and qualitative data sources at 23 community health centers linked to one of 15 Xpert testing sites between November 2016 and May 2017 to assess health systems infrastructure for hub-and-spoke Xpert testing. Data sources included a standardized site assessment survey, routine TB notification data, and field notes from site visits.

resultsChallenges with Xpert implementation occurred at every step of the diagnostic evaluation process, leading to low overall uptake of testing. Of 2192 patients eligible for TB testing, only 574 (26%) who initiated testing were referred for Xpert testing. Of those, 54 (9.4%) were Xpert confirmed positive just under half initiated treatment within 14 days (n = 25, 46%). Gaps in required infrastructure at 23 community health centers to support the hub-and-spoke system included lack of refrigeration (n = 14, 61%) for sputum testing and lack of telephone/mobile communication (n = 21, 91%). Motorcycle riders responsible for transporting sputum to Xpert sites operated variable with trips once, twice, or three times a week at 10 (43%), nine (39%) and four (17%) health centers, respectively. Staff recorded Xpert results in the TB laboratory register at only one health center and called patients with positive results at only two health centers. Of the 15 Xpert testing sites, five (33%) had at least one non-functioning module. The median number of tests per day was 3.57 (IQR 2.06-4.54), and 10 (67%) sites had error/invalid rates > 5%.

conclusionsAlthough Xpert devices are now widely distributed throughout Uganda, health system factors across the continuum from test referral to results reporting and treatment initiation preclude effective implementation of Xpert testing for patients presenting to peripheral health centers. Support for scale up of innovative technologies should include support for communication, coordination and health systems integration.

Indexed as

Genetic TestingCross-Sectional StudiesDelivery of Health CareHealth Services ResearchHumansTuberculosisUgandaDiagnosisGeneXpertHealth systemInfectious diseaseInfrastructureTuberculosis

Identifiers

PMID32131814
PMCPMC7057496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.